Innovus Pharmaceuticals (OTC:INNV) announced today that it has inked an agreement with its current partner, Acon Laboratories, to sell Acon’s FDA-cleared glucose monitor, test strips and lancet device.
The San Diego, Calif.-based company plans to sell Acon’s glucose testing kit with its GlucoGorx glucose supplement.
Innovus touted the kit as being able to provide glucose levels within 4 seconds. The company said that with an FDA-cleared glucometer and test strips in its portfolio, it’s eligible to enter reimbursement and government supply programs.
“We are proud to expand our partnership and to be working with Acon to add the GlucoGorx glucose monitor, strips and lancet device for our customers. The creation of a kit for monitoring a diabetic’s blood suger levels expands our GlucoGorx clinical supplement offerings,” president & CEO Bassam Damaj said in prepared remarks.
“We strongly believe our GlucoGorx customers will be able to use our FDA cleared kit to monitor their blood sugar levels from the convenience of their own homes. We are excited that Innovus Pharma is entering this large glucose monitoring market and we look forward to offering GlucoGorx and the GlucoGorx Kit in the first half of 2018.”
INNV shares closed at 8¢ apiece on Friday, up +1.6%.
